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1. Introduction
Hemophilia is hereditary x-chromosomal recessive disorders. Hemophilia A is caused by
deficiency or absence of coagulation factor VIII and hemophilia B is caused by that of coagu‐
lation factor IX. The prevalence is reported as one in 5000 in the male population and one in
10000 overall. These diseases are classified into three categories according to serum coagula‐
tion factor activity; severe (<1%), moderate (1-5%), or mild (>5%). The particular hemophilic
manifestation is intra-articular bleeding. Intra-articular bleeding is usually occurred by trau‐
ma but also often spontaneously. Approximately 5% of first bleeding episodes in hemophilic
boys are into a joint. The average age of first intra-articular bleeding is 1.91±0.91 years old
and the median age of that is 1.63 years old [1]. A joint in which four or more recurrent
bleedings have occurred in the prior 6 months is defined as target joint. In the United States,
2.3% of children 2-5 years of age enrolled in the Universal Data Collection Project have tar‐
get joints [2]. Most of target joints have hemophilic synovitis, which is characterized by in‐
flammation, angiogenesis and fibrosis [3] and develop hemophilic arthroplasty which is
characterized by cartilage and bone destruction.
The average annual intra-articular bleeding number were higher in the episodic-therapy
group than in the prophylaxis group and the relative risk of MRI-detected joint damage
with the episodic was 6-fold greater compared with prophylactic group [4]. Therefore, it is a
clear the relationship between intra-articular bleeding and hemophilic arthropathy. Howev‐
er, the number and volume of intra-articular bleedings which result in target joint and ar‐
thropathy is not understood. Experimental pathgenetic studies were reported and many
points of the pathogenesis are still remained as poorly understood points [2,5,6].
As for radiological evaluation methods of hemophilic arthropathy, there are three major sys‐
tems. De Palma classification is classical progressive system and popular in Japan. This sys‐
tem classified hemophilic arthropathy from grade 0 (normal) to grade IV (end-stage) [7].
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Arnold-Hilgartner classification is also classical progressive system and classified from stage
0 (normal) to stage V (end-stage) [8]. Pettersson score is recommend additive scoring system
by World Federation of Hemophilia (WFH) [9]. 8 categories in this system have 0 (normal)
to 2 (worse) points and totally scored from 0 (normal) to 13 points (worst). There are classi‐
cal and authorized good systems but it may need to improve them, because their inter-ob‐
server reliabilities were poor [10].
As for MRI evaluation methods, there were several reports since 2000 [11-13], and WFH rec‐
ommended MRI scale and modified version were published from the international prophy‐
laxis study group [14, 15].
The causative mechanism of hemophilia was recognized in the 1950s [16], and concentrates
for coagulation factor replacement became generally available since 1960s, however the easy
administration of the concentrates resulted in transmission of viral infection including hepa‐
titis C (HCV) and Human immunodeficiency virus infection (HIV) during the 1980s [17]. Al‐
so, the appearance of allo-immune antibody (inhibitor) against deficient coagulation factor
is severe adversity. Product development such as recombinant concentrates has especially
improved therapeutic safety and availability [18], resulting in the possibility of performing
elective orthopedic surgery and prevention of bleeding episodes. The routine administration
of prophylactic treatment has undoubtedly resulted in a greatly improvement in the quality
of life and life expectancy of hemophilic patients. However, many of young hemophilic
adults still have severe destructive joints as a result of repeated intra-articular bleeding dur‐
ing their early years.
For hemophilic arthropathy, there are two major surgical options which are synovectomy
for early stage (hemophilic synovitis) and total joint arthroplasty (TJA) for end stage. At pro‐
gressive stage, there are not good surgical options so that several usual orthopedic options
are tried: anti-inflammatory drugs, corticosteroids, joint infusion of hyaluronic acid or corti‐
costeroids, braces and rehabilitation. However many of them are progressed to end-stage.
Total joint arthroplasty (TJA) is effective procedure in the management of hemophilic ar‐
thropathy for them [19].
2. Major surgery for hemophilia
In our hospital, 126 major surgeries for 80 patients have been performed between June 2006
and June 2012 in which were 96 surgeries for 63 hemophilia A, 28 surgeries for 16 hemophil‐
ia B, and 2 surgeries for 2 other coagulation disorders. 18 surgeries with inhibitor were in‐
cluded. The average age at operation was 39.03 years (13 ~ 60 years). As for virus infection,
HBs antigen positive ratio was 1.5% (2/126 surgeries), HCV antibody positive ratio was
89.7% (113/126), HIV antibody positive ratio was 33.3% (42/126) and both HCV and HIV an‐
tibody positive ratio was 31.7% (41/126).
Major surgery such as TJA is never easily undertaking in hemophilic patients. It required
bleeding control at peri-operative periods, management for viral infection and inhibitor, and
treatment for complication subsequently to bleeding.
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As for bleeding control, guidelines were published[20, 21], in which the aim serum factor
level at peri-operative period is explained clearly. However it is difficult without the sup‐
port of hematologists so that major surgeries are usually performed at hemophilia centers.
As for HIV infection, CD4 cell counts had been important factor as major influence factor on
bacterial infection in the early literatures [22-25]. HIV medical treatment has drastically im‐
proved during the last decade. In the recent literatures [26-29] and our experience, there was
no evidence to suggest that bacterial deep infection at surgical site was influenced on the de‐
cline of CD4 cell counts. However HIV-positive patients whose CD4 cell counts is less than
50 cell/mm3 have a considerable risk of the occurrence of opportunistic infection at peri-op‐
eraive periods.
Most hemophilia adult patients infected hepatitis C virus at 1980s and long period of the vi‐
rus carrier results in hepatic insufficiency and hepatoma. The treatment for chronic hepatitis
has also improved, however it was not good enough to control it. According to our clinical
experiences, severe hepatic insufficiency has been influenced on the fatal ratio after major
surgery.
Between 10-30% of patients with hemophilia A and 2-5% of patients with hemophilia B de‐
velop an inhibitor to FVIII or FIX [30]. Intra-articular bleedings in inhibitor patients have a
more negative impact on their joint function and daily life. They desire to reduce the pain
and improve function at affected joint. However surgical treatments may be deferred until
patients suffer from increasingly severe pain and progressive physical incapacity find no
other options, due to the higher bleeding risks associated with surgery [31]. In fact, there are
some surgical reports for inhibitors, but many of them are a few cases reports [32]. Guide‐
lines for inhibitor [33] were also published, but bleeding control plan at peri-operative peri‐
ods is not established. We believe surgical treatments for inhibitor should be performed at
hemophilic center.
Delayed wound healing is the major complication subsequently to bleeding. In hemophilia
B mice, dermal wound healing is delayed and can be treated with factor IX replacement
therapy to restore thrombin generation. This delay is associated with bleeding into granula‐
tion tissue [34]. In our hospital, there were 3.3% delayed wound healings.
3. Total joint arthroplasty
TJA has been available as a final option in the end-stage hemophilic arthropathy with signif‐
icantly reduced quality of life. The major objectives of TJA are to reduce the pain in the af‐
fected joint and improve the joint function. These effects are influenced on the adjacent
joints beneficially. In addition, the frequency and number of the intra-articular bleeding is
significantly reduced. Thereby, their life-style and quality of life significantly improved. The
indications are adult hemophilia patients with severe destructive arthropathy and subjective
dysfunction. Adult means the patient’s epiphyses are closed. We have performed total hip
arthroplasty for 18 years boy. Their dysfunction have been started from childhood and
Total Joint Arthroplasty for Hemophilia
http://dx.doi.org/10.5772/53232
293
made worse gradually. They are satisfied to live on their ability even if they have severe de‐
structive arthropathies. These cases are not indication subjectively. Total knee or hip arthro‐
plasty (TKA, THA) are generally performed and total elbow and ankle arthroplasty (TEA,
TAA) are rarely performed. However the most common affected joints are elbow, knee and
ankle. The average of operation is around forty [35, 36]. In our hospital, 81 total joint arthro‐
plasty were performed included 59 TKAs, 20 THAs, 1TEA and 1TAA and average age were
44.5. (figure 1, 2)
Figure 1. A 18-year-old hemophilia A patient without inhibitor. No virus infection. Severe hemophilic arthropathy of
the right knee. His knee range of motion was improved at four years after surgery: extension was -30 degrees to 0
degrees and flexion was 90 degrees to 110 degrees. (a): pre-operative radiography; (b) at one month radiography (c)
at four year radiography
Figure 2. A 23-year-old hemophilia A patient with inhibitor. HCV is positive. Severe hemophilic arthropathy of the
right hip. His back pain and tilted pelvis are improved after surgery. (a): pre-operative radiography; (b) just operative
radiography (c) at five year radiography
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As for surgical technique, we believe orthopedic surgeons do not need special skills when
deficient factor level is kept with concentrate adequately. However, there are some careful
points on TJA for hemophilia, in addition to the aforementioned surgical risks for hemophil‐
ia, which are higher infection rate, higher revision rate or shorter durability (table 1), and the
occurrence of deep venous thrombosis (DVT).
Authers Year Number ofTJA
Average of
Follow-up
(years)
Infection
rate
(%)
Aseptic loosening
rate
(%)
Cohen et al 2000 21 TKAs 5.6 10 0
Norian et al 2002 53 TKAs 5 13.2 9.4
Sheth et al 2004 14 TKAs 6.4 0 0
Goddard et al 2010 70 TKAs 9.2 1.5 8.6
Habermann et al 2007 15 THAs 11 6.7 6.7
Miles et al 2008 34 THAs 6.3 3 9
Yoo et al 2009 23 THAs 7.7 0 4.8
Powell et al 2005 35 TKAs16 THAs 6.9
TKA:14.3
THA:6.3 0
Wang et al 2012 40 TKAs18 THAs 10.7
TKA:13
THA:0
TKA:2.5
THA:5.6
Table 1. Infection and aseptic loosening rate after TJA in hemophilia including current study [35-38,40-44]
As for the infection after TJA, most reports show a deep infection rate of 10-16% [35-41], and
our result shows much lower infection rate of 2.5 (2/81). However, these rates are higher
than infection rate of 1-2% consistently reported in the literatures in the general population
[45]. HIV infection had been important factor as major influence factor on bacterial infection,
however the recent clinical results suggest there is no difference in the infection rate be‐
tween HIV positive and negative. It is unclear why the ratio after TJA for hemophilia is
much higher than that for non-hemophilia. The hypothesis that much frequent venous self-
infusion is influenced on highly infection rate [40] is one of possibilities, but there is no evi‐
dence as yet.
As for durability, there are a few long clinical reports. When revision for aseptic mechanical
failure was considered as endpoint, the survival rate for 40 TKAs at 10 years was 93%. The
survival rate for 18 THAs at 8.5 years was 89% [36]. According to clinical result for 60 TKAs
at a mean follow-up of 9.2 years, Kaplan-Meier analysis using infection and aseptic loosen‐
ing as endpoint showed the survival rate at 20 years to be 94.0% [35]. These survival rates
were similar to that in young non-hemophilia patients [46,47], however we believe it is not
good enough rate for young hemophilic patients who have multi-arthropathy.
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Hemophilia patients are often considered that their risk of DVT is lower by virtue of their
bleeding disorder. However, they have as same risk of DVT as non-hemophilic patients, be‐
cause the coagulation factor level is normalized by administration of concentrates at peri-
operative periods. In our hospital, all patients use compression devices and not administrate
drugs such as heparin or aspirin. Thrombosis has been checked by ultrasound and not de‐
tected at pre- and post-operation. Subclinical DVT was observed in 10% of hemophilia pa‐
tients undergoing major orthopedic surgery [48]. According to the simple questionnaires
survey at hemophilia treatment center in the United States, 78% provided thrombo-prophy‐
laxis to selected patients. Of those providing of thrombo-prophylaxis, 67% used compres‐
sion stocking or devices, 24% used low molecular weight heparin, 1% fondaparinux, 3%
unfractionated heparin. 4% warfarin and 1% aspirin [49].
Finally, the cost of hemophilia treatment is major economical concern. The concentrate cost
is occupied of major part of TJA cost and it is depended on the patient body weight. And the
price of concentrates and insurance situation are quite differences internationally, so that we
introduced our situation in this chapter. The cost is too expensive to performed surgery
without insurance coverage, however Japanese general health insurance is covered with
most of the cost, fortunately. The cost of TJA at peri-operative periods about two weeks is
forty to fifty thousand dollars for average Japanese hemophilic patients without inhibitor
(50-70kg). The cost for inhibitor cases is about 5 to 10-folds.
Total joint arthroplasty for hemophilia is a challenging surgery and never a simple under‐
taking, however hemophilia patient need to improve their life style and release severe pain.
We believe it is a safe and effective procedure in the management of hemophilic arthropathy
at hemophilia centers.
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